Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Winter, Jane N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autologous stem cell transplantation; Radioimmunotherapy; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB; TOSITUMOMAB I 131;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIARRHEA; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ENDOCARDITIS; FEVER; HEART ARRHYTHMIA; HUMAN; INFECTION; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NONHODGKIN LYMPHOMA; PNEUMONIA; RADIOIMMUNOTHERAPY; REVIEW; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 7944223710     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.s.005     Document Type: Article

References (27)

1. Philip T, Gugliemi C, Hagenbeck A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
2. van Besien K, Loberiza FJ, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102:3521-3529.
3. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100:1141-1152.
4. Schouten H, Quian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21:3918-3927.
5. Winter J, Inwards D, Erwin W et al. Zevalin-close escalation followed by high-dose BEAM and autotransplant in CD20+ relapsed or refractory non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant 2004; 10:28-29.
6. Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:588-595.
7. Winter J, Inwards D, Erwin W, et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood 2002; 100(suppl):411a (Abstract #1597).
8. Johnston P, Ansell S, Micallef I, et al. Changes in pulmonary function following high dose therapy with BEAM conditioning and stem cell transplantation for Hodgkin's or non-Hodgkin's lymphoma. Presented at: Pan-Pacific Lymphoma Conference; June 19-22, 200 1; Maui, Hawaii.
9. Nademanee A, Molina A, Forman S, et al. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood 2002; 100(suppl):182a (Abstract #679).
10. 90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial. Proc Am Soc Clin Oncol 2004; 23:557 (Abstract #6504).
11. Nademanee A, Fung H, Molina A. The City of Hope experience with novel transplant regimens that incorporate standard and escalated dose 90-yttrium ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin's lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI). Biol Blood Marrow Tanspl 2004; 10:28 (Abstract #58).
12. Fung H, Forman S, Nademanee A, et al. A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity. Blood 2003; 102(suppl):248a (Abstract #870).
13. Kaminski M, Zasadny K, Francis I, et al. Radioimmunotherapy of B-cell lymphoma with 131I and-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459-465.
14. Kaminski M, Zasadny K, Francis I, et al. Iodine I 131 tositumomab radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1981.
15. Kaminski M, Estes J, Zasadny K, et al. Radioimmunotherapy with iodine I 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-1266.
16. Kaminski M, Zelenetz A, Press O, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-3928.
17. Vose J, Wahl R, Saleh M, et al. Multicenter phase II study of iodine I 131 tositumomab for chemotherapy-relapsed/refractory low grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18:1316-1323.
18. Knox S, Goris M, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2:457-470.
19. Witzig T, White C, Wiseman G, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
20. Witzig T, Gordon L, Cabanillas F, et al. Randomized controlled trial of yttrium-90-lableled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
21. Witzig T, White C, Gordon L, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
22. Press O, Eary J, Appelbaum F, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219-1224.
23. Liu S, Eary J, Petersdorf S. Follow-up of relapsed B cell lymphoma patients treated with I-131-labeled anti-CD20 (anti-B1 antibody) and autologous stem cell rescue. J Clin Oncol 1998; 16:3270-3278.
24. Press O, Eary J, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934-2942.
25. Gopal A, Rajendran J, Petersdorf S, et al. High-dose chemo-radioimmune therapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158-3162.
26. Vose J, Bierman P, Lynch J, et al. Long term results of radioimmunotherapy with Bexxar/BEAM and autologous stem cell transplantation (ASCT) for chemotherapy resistant aggressive non-Hodgkin's lymphoma (NHL). Blood 2003; 102(suppl):248a (Abstract #872).
27. Pagel J, Matthews D, Appelbaum F, et al. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant 2002; 29:807-816.